[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]

Inclusion Criteria: 1. Must have primary residence in the United States 2. Must be ≤ 92 days postpartum 3. Must be women aged 22-45 years who had onset of a major depressive episode any time during pregnancy or within 4 weeks following delivery 4. Must own or have regular access to a smartphone (Android or iOS smartphone with a recent, supported operating system), and has reliable Wi-Fi access or sufficient data plan to engage with assigned treatment condition for the duration of the study 5. Participants must have current mild-moderate depression as measured by the HAMD-6 score \>7 and \<13 at screening 6. Participant must have a form of TAU, defined as clinician supervised outpatient care management and includes follow-up visits, medication, psychotherapy, or some combination thereof 7. TAU must be regularly scheduled or stable for at least 4 weeks prior to baseline (BL) visit Exclusion Criteria: 1. Gestation less than 28 weeks 2. HAMD-6 score ≤7 or ≥13 (severe depression) at screening 3. Currently pregnant or plans to become pregnant within the next 8 weeks 4. History of drug and/or alcohol use disorder within the past 12 months 5. Lifetime history of suicide attempt or ideation with a plan and intent to harm oneself during the current episode of PPD 6. Current or lifetime psychosis 7. Current or lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, and/or homicidal or infanticidal ideation 8. History of antidepressant treatment with ketamine/esketamine, electroconvulsive therapy, vagal nerve stimulation, or a deep brain stimulation device 9. History of treatment-resistant depression (TRD) 10. Fetal demise within the past 18 months